Rezolute rises as drug shows promise for rare low blood sugar disorders

Shares of drug developer Rezolute RZLT.O rise 2.1% to $1.95 premarket

Co says late-stage trial of ersodetug in congenital hyperinsulinism missed main goals but showed drug activity

Congenital HI causes frequent severe drops in blood sugar; all 59 patients opted for extension study, RZLT says

Some children stopped other treatments, relying only on ersodetug, co says

Expanded access program in tumor-related HI saw 75% patients stop hospital glucose infusions, RZLT says

Co plans FDA meeting early this year

Ersodetug aims to block excess insulin effects; drug generally well-tolerated so far, co says

As of last close, stock down ~19% over the past year